Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 15/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821991 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP2D6APEX1PMP22ACACB | |
| SCHEMBL13033633 | 0.84 | ACACB (0.56) | ACACBSIGMAR1SLC6A4 | |
| SCHEMBL15699361 | 0.84 | ACACB (0.56) | ACACBSIGMAR1SLC6A4 | |
| SCHEMBL21089970 | 0.81 | CYP1A2 (0.61) | CYP1A2CYP2D6APEX1PMP22ACACB | |
| SCHEMBL31545367 | 0.81 | ACACB (0.61) | ACACB | |
| SCHEMBL5018760 | 0.79 | NQO1 (0.61) | ACACBSIGMAR1 | |
| SCHEMBL7074595 | 0.79 | NQO1 (0.50) | ACACBSIGMAR1 | |
| SCHEMBL21015668 | 0.78 | ACACB (0.51) | ACACB | |
| SCHEMBL18494260 | 0.78 | ACACB (0.54) | ACACB | |
| SCHEMBL19465105 | 0.78 | ACACB (0.51) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | THERAPHARM GMBH | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162290-A1 | METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF | C5, C3AR1, SPR | CYP1A2 1585/4885CYP2D6 556/4885APEX1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.